Catalyst Pharmaceuticals (CPRX) Tops Q4 EPS by 11c; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CPRX Hot Sheet
Price: $31.49 --0%
Financial Fact:
Loss from operations: -3.91M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Loss from operations: -3.91M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q4 EPS of $0.31, $0.11 better than the analyst estimate of $0.20. Revenue for the quarter came in at $60.76 million versus the consensus estimate of $56.85 million.
GUIDANCE:
Catalyst Pharmaceuticals sees FY2023 revenue of $375-385 million, versus the consensus of $382.7 million.
For earnings history and earnings-related data on Catalyst Pharmaceuticals (CPRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- Grainger (GWW) Tops Q3 EPS by 87c ; Offers Guidance
- L.B. Foster (FSTR) Reports In-Line Q3 EPS ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
